91 related articles for article (PubMed ID: 19036118)
1. Targeting Wnt pathway in lymphoma and myeloma cells.
Schmidt M; Sievers E; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Br J Haematol; 2009 Mar; 144(5):796-8. PubMed ID: 19036118
[No Abstract] [Full Text] [Related]
2. In vivo efficacy of griseofulvin against multiple myeloma.
Kim Y; Alpmann P; Blaum-Feder S; Krämer S; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Leuk Res; 2011 Aug; 35(8):1070-3. PubMed ID: 21112630
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Wnt/beta-catenin pathway in multiple myeloma.
Schmeel LC; Schmeel FC; Kim Y; Endo T; Lu D; Schmidt-Wolf IG
Anticancer Res; 2013 Nov; 33(11):4719-26. PubMed ID: 24222106
[TBL] [Abstract][Full Text] [Related]
4. Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid.
Schmidt M; Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(3):325-33. PubMed ID: 21576405
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model.
Kim Y; Schmidt M; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(6):887-93. PubMed ID: 22021681
[TBL] [Abstract][Full Text] [Related]
6. In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.
Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Leuk Res; 2012 May; 36(5):598-600. PubMed ID: 22386728
[TBL] [Abstract][Full Text] [Related]
7. Increased in vivo efficacy of lenalidomide by addition of piroctone olamine.
Kim Y; Alpmann P; Blaum-Feder S; Krämer S; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(1):99-103. PubMed ID: 21282741
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells.
Minke KS; Staib P; Puetter A; Gehrke I; Gandhirajan RK; Schlösser A; Schmitt EK; Hallek M; Kreuzer KA
Eur J Haematol; 2009 Mar; 82(3):165-75. PubMed ID: 19067737
[TBL] [Abstract][Full Text] [Related]
9. In vitro efficacy of cinnarizine against lymphoma and multiple myeloma.
Schmeel LC; Schmeel FC; Kim Y; Blaum-Feder S; Endo T; Schmidt-Wolf IG
Anticancer Res; 2015 Feb; 35(2):835-41. PubMed ID: 25667464
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow stromal cell-derived Wnt signals as a potential underlying mechanism for cyclin D1 deregulation in multiple myeloma lacking t(11;14)(q13;q32).
Bueno C; Lopes LF; Menendez P
Blood Cells Mol Dis; 2007; 39(3):366-8. PubMed ID: 17632021
[No Abstract] [Full Text] [Related]
11. Drugging the Wnt pathway: problems and progress.
Garber K
J Natl Cancer Inst; 2009 Apr; 101(8):548-50. PubMed ID: 19351922
[No Abstract] [Full Text] [Related]
12.
Schmeel LC; Schmeel FC; Schmidt-Wolf IGH
Anticancer Res; 2017 Jul; 37(7):3513-3520. PubMed ID: 28668840
[TBL] [Abstract][Full Text] [Related]
13. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway.
Shan BE; Wang MX; Li RQ
Cancer Invest; 2009 Jul; 27(6):604-12. PubMed ID: 19440933
[TBL] [Abstract][Full Text] [Related]
14. Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets.
Giuliani N; Mangoni M; Rizzoli V
Exp Hematol; 2009 Aug; 37(8):879-86. PubMed ID: 19446662
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Efficacy of Naftifine Against Lymphoma and Multiple Myeloma.
Schmeel LC; Schmeel FC; Blaum-Feder S; Schmidt-Wolf IG
Anticancer Res; 2015 Nov; 35(11):5921-6. PubMed ID: 26504016
[TBL] [Abstract][Full Text] [Related]
16. Effect of Wnt inhibitors in pancreatic cancer.
Wall I; Schmidt-Wolf IG
Anticancer Res; 2014 Oct; 34(10):5375-80. PubMed ID: 25275031
[TBL] [Abstract][Full Text] [Related]
17. Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma.
Hu J; Dong A; Fernandez-Ruiz V; Shan J; Kawa M; Martínez-Ansó E; Prieto J; Qian C
Cancer Res; 2009 Sep; 69(17):6951-9. PubMed ID: 19690140
[TBL] [Abstract][Full Text] [Related]
18. Flunarizine exhibits in vitro efficacy against lymphoma and multiple myeloma cells.
Schmeel LC; Schmeel FC; Kim Y; Blaum-Feder S; Endo T; Schmidt-Wolf IG
Anticancer Res; 2015 Mar; 35(3):1369-76. PubMed ID: 25750287
[TBL] [Abstract][Full Text] [Related]
19. Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/beta-catenin signaling.
Prasad CP; Rath G; Mathur S; Bhatnagar D; Ralhan R
Chem Biol Interact; 2009 Oct; 181(2):263-71. PubMed ID: 19573523
[TBL] [Abstract][Full Text] [Related]
20. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]